

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention (CDC)
“Public Health and Social Services Emergency Fund”
Public Health Emergency Response (PHER) Phase II
Funding for Vaccination Campaign Planning

I. Authorization and Intent

Announcement Type: Supplemental – Type 3

Funding Opportunity Number: CDC-RFA-TP09-90201-H1N109

Catalog of Federal Domestic Assistance Number: 93.069

Application Deadline: August 13, 2009

Authority: Sections 317(a) and (e) of the Public Health Service Act, as amended, [42 U.S.C. §§ 247b(a), (e)]

Purpose

Additional pandemic influenza preparedness funding is available through the Public Health and Social Services Emergency Fund to upgrade state and local preparedness and response capacity. These funds, known as PHER Phase II funds, supplement the \$260 million provided to state and local health departments through the Public Health Emergency Response grant (PHER Phase I) for vaccination planning and for laboratory testing, epidemiology, surveillance, and other associated pandemic preparedness and response activities. A total of \$248 million in PHER Phase II funding is available to further accelerate planning for a national vaccination campaign for H1N1 influenza in the fall of 2009.

The PHER Phase II funding is intended to provide additional resources to augment the mass vaccination planning and implementation preparedness activities described in the PHER Phase I funding opportunity announcement (FOA) released by CDC on July 9, 2009. PHER Phase II funding also may be used for vaccine delivery, vaccine administration, and related communications planning and implementation.

The PHER Phase I FOA described activities expected of awardees with respect to pandemic influenza planning and response, providing guidance in two specific areas:

- Focus Area 1: Vaccination, Antiviral Distribution/Dispensing and Administration, Community Mitigation, and Other Associated Pandemic Preparedness and Response Activities; and,
- Focus Area 2: Laboratory, Epidemiology, Surveillance, and Other Associated Pandemic Preparedness and Response Activities.

This PHER Phase II award provides additional resources for Focus Area 1 only, with a special emphasis on mass vaccination readiness. Funding is not provided for Focus Area 2 activities. This document is not intended to specify new mass vaccination-related activities, but rather to accelerate the speed in which these activities can be accomplished with additional funding. The goal of this additional funding is to assure readiness at the state and local levels for implementation of a large-scale mass vaccination campaign against H1N1 influenza expected to begin in the fall of 2009. Prior to requesting these PHER Phase II funds, awardees should review the objectives described in the PHER Phase I FOA as well as the additional information provided below.

Awardees are expected to assess mass vaccination readiness through a variety of methods, including but not limited to:

- Reviewing after-action reports (AARs) of previous exercises/real events; and,
- Identifying preparedness gaps by using the CDC Gap Analysis Tool (scheduled to be distributed to PHER awardees on or before August 11, 2009).

Background

On April 26, 2009, the Acting Secretary of Health and Human Services declared a public health emergency as a result of the detection of 20 known cases of individuals infected by a swine-origin influenza A virus, now known as novel H1N1 influenza, in the United States. On June 11, 2009, the World Health Organization declared the first pandemic in more than 40 years in recognition of widespread, sustained human-to-human transmission of the virus in multiple regions around the globe. In light of the threat the pandemic poses to the nation's public health and security, Congress appropriated funding, through the 2009 Supplemental Appropriations Act, for the Public Health and Social Services Emergency Fund to prepare for and respond to an influenza pandemic. This funding provides the U.S. Department of Health and Human Services (HHS) and other federal and state agencies with resources to respond to ongoing and emerging outbreaks of novel H1N1 influenza virus in the United States, protect the public health, accelerate efforts in responding to the current global influenza pandemic, and prepare for additional waves of the current pandemic or outbreaks of other avian, swine, and human influenza viruses.

II. Program Implementation

Recipient Activities

Awardees are expected to use this additional funding for accelerated H1N1 influenza vaccination planning and response activities described in Focus Area 1 of the PHER Phase I FOA (see below), to assess their current capabilities in pandemic influenza response, and to address remaining gaps in mass vaccination planning.

Focus Area 1: Vaccination, Antiviral Distribution/Dispensing and Administration, Community Mitigation, and Other Associated Pandemic Preparedness and Response Activities. The purpose of Focus Area 1 is to conduct accelerated planning activities to identify and address gaps in existing plans and to initiate implementation of activities in preparation for a possible mass vaccination campaign. During a pandemic,

reducing transmission can be accomplished by increasing immunity to the virus through vaccination and reducing exposure to the virus. Community mitigation measures could also reduce people's exposure to the virus throughout all phases of the vaccine campaign. Awardees should plan for both vaccination and community mitigation activities, which can be complemented by use of antiviral drugs. Costs for training and education of the public health workforce to support these activities will be approved if they are within the scope of the grant.

Recommended awardee activities include development of comprehensive communication strategies regarding vaccine planning and implementation, as well as all other suggested activities outlined in the PHER Phase I FOA, as summarized below:

- Vaccination planning for public health-organized clinics
- Identifying and engaging private-sector partners for potential vaccine administration
- Defining potential vaccine-receiving sites
- Enhancing cold-chain capacity where needed
- Safety monitoring
- Tracking vaccine and vaccine supplies
- Monitoring and reporting of vaccine doses administered
- Initiating contracts with community vaccinators and others for early implementation activities
- Communications planning
- Planning for potential antiviral distribution/dispensing and administration
- Community mitigation planning and strategies
- Community planning and exercising

III. Award Information and Requirements

Eligible Applicants

Financial assistance is available only to the 62 eligible applicants of PHER Funding Opportunity Announcement CDC-RFA-TP09-902-H1N109.

Funding

CDC will administer a total of \$248 million in PHER Phase II funding to support accelerated planning for a national vaccination campaign for H1N1 influenza in the fall of 2009. To assure that all awardees have sufficient resources to conduct the activities described in this guidance, the formula for this award will include base funding plus additional funding based on population estimates (**Appendix 1**).

IV. Content and Form Submission

Application Requirements

To assure that awardees have ready access to the funds necessary for accelerated vaccination campaign planning, CDC will streamline the submission requirements for the

PHER Phase II awards. The requirements for the PHER Phase II application, to be submitted via www.grants.gov, include:

- A letter, co-signed by the applicant's preparedness program director, immunization program director, and authorized fiscal officer, requesting the *entire award* be allocated (see funding table in Appendix 1). The letter must include language that states that the applicant will submit the required gap analysis, work plan, and revised, combined PHER Phase I and Phase II budget on or before August 31, 2009.
- Form 424A
- A general budget with a budget justification describing how the applicant intends to use the **PHER Phase II** funding.

Application Deadline

Applications are due by 2 p.m. EDT on August 13, 2009, and are to be electronically submitted to www.grants.gov.

V. Award Administration Information

Award Notices

Funds are expected to be awarded on or before August 21, 2009. CDC may restrict up to 20% of the PHER Phase II funds until the applicant completes the additional requirements described below.

Reporting Requirements

All previously stated reporting requirements remain unchanged and in effect.

In addition, awardees must submit to PERFORMS by September 15, 2009, letters indicating they have comprehensive, up-to-date plans in place for a potential H1N1 influenza mass vaccination campaign. CDC does not plan at this time to require awardees to submit their mass vaccination plans for review.

Additional Requirements

On or before August 31, 2009, awardees must submit the following into PERFORMS:

- **Gap Analysis:** Using the gap analysis tool provided by CDC, awardees will identify any remaining gaps in state, local, territorial, and tribal pandemic preparedness in the two focus areas (vaccination, antiviral distribution/dispensing and administration, and community mitigation; and laboratory, epidemiology, and surveillance). The gap analysis is intended to help awardees identify priority areas for improvement and to determine how funds are to be directed.
- **Work Plan:** Awardees will use the results of the gap analysis to prioritize remaining gaps, determine which gaps are the most critical/highest priority areas and develop work plans to describe how these gaps will be addressed. Work plans will be for activities to be completed in 12 months.

- Detailed Budget: Awardees must develop a combined and detailed 12-month PHER (Phases I and II) budget for Focus Area 1. Awardees also must submit a separate, detailed PHER Phase I budget for Focus Area 2. Budgets should reflect how funds will be used to address any remaining gaps in pandemic preparedness identified through the gap assessment. **Awardees may use a portion of their PHER funding (Phases I and II) to request direct assistance (DA) personnel.**

Note: Awardees are only required to conduct one gap analysis and to develop one work plan that addresses both Phase I and Phase II activities. A timeline of important dates and deliverables is included in **Appendix 2**.

CDC recognizes that some jurisdictions may need access to more than 80% of the awarded funds prior to completing all of the August 31 deliverables. CDC *does not* encourage awardees to delay or slow progress toward completing preparation due to funding restrictions. Awardees that need additional funds over and above the 80% should discuss their needs with their Division of State and Local Readiness project officer. Additionally, awardees that need access to restricted funds are strongly encouraged to complete their gap assessments, work plans, and detailed budgets prior to August 31. Restrictions on all remaining funds will be lifted following receipt of an acceptable gap analysis, work plan, and detailed, combined budget.

VI. Agency Contacts

CDC encourages inquiries concerning this announcement. For general questions, contact:

Technical Information Management Section
Department of Health and Human Services
CDC Procurement and Grants Office
2920 Brandywine Road, MS E-14
Atlanta, GA 30341
Telephone: 770-488-2700

For programmatic technical assistance, contact the appropriate Division of State and Local Readiness project officer in **Appendix 3**. For financial, grants management, or budget assistance, contact the appropriate Procurement and Grants Office grants management specialist in **Appendix 4**.

**Appendix 1
Public Health Emergency Response (PHER)
Phase II Funding**

Awardee	Phase II Focus Area 1	Phase II Focus Area 2	FY 2009 PHER Phase II Funding Total
Alabama	\$3,981,585	\$0	\$3,981,585
Alaska	\$1,861,553	\$0	\$1,861,553
American Samoa	\$531,185	\$0	\$531,185
Arizona	\$4,827,276	\$0	\$4,827,276
Arkansas	\$3,016,715	\$0	\$3,016,715
California	\$15,804,211	\$0	\$15,804,211
Chicago	\$2,528,828	\$0	\$2,528,828
Colorado	\$4,064,869	\$0	\$4,064,869
Connecticut	\$3,391,156	\$0	\$3,391,156
Delaware	\$1,960,526	\$0	\$1,960,526
District of Columbia	\$1,313,787	\$0	\$1,313,787
Florida	\$11,261,100	\$0	\$11,261,100
Georgia	\$6,552,677	\$0	\$6,552,677
Guam	\$592,280	\$0	\$592,280
Hawaii	\$2,193,640	\$0	\$2,193,640
Idaho	\$2,291,288	\$0	\$2,291,288
Illinois	\$6,895,159	\$0	\$6,895,159
Indiana	\$4,906,704	\$0	\$4,906,704
Iowa	\$3,109,100	\$0	\$3,109,100
Kansas	\$2,991,464	\$0	\$2,991,464
Kentucky	\$3,769,550	\$0	\$3,769,550
Los Angeles	\$6,367,873	\$0	\$6,367,873

Awardee	Phase II Focus Area 1	Phase II Focus Area 2	FY 2009 PHER Phase II Funding Total
Louisiana	\$3,813,631	\$0	\$3,813,631
Maine	\$2,213,106	\$0	\$2,213,106
Marshall Islands	\$532,619	\$0	\$532,619
Maryland	\$4,530,183	\$0	\$4,530,183
Massachusetts	\$4,973,437	\$0	\$4,973,437
Michigan	\$6,947,495	\$0	\$6,947,495
Micronesia	\$558,278	\$0	\$558,278
Minnesota	\$4,288,110	\$0	\$4,288,110
Mississippi	\$3,070,495	\$0	\$3,070,495
Missouri	\$4,652,662	\$0	\$4,652,662
Montana	\$2,009,713	\$0	\$2,009,713
Nebraska	\$2,454,172	\$0	\$2,454,172
Nevada	\$2,846,559	\$0	\$2,846,559
New Hampshire	\$2,209,503	\$0	\$2,209,503
New Jersey	\$6,207,674	\$0	\$6,207,674
New Mexico	\$2,554,680	\$0	\$2,554,680
New York	\$7,484,987	\$0	\$7,484,987
New York City	\$5,432,412	\$0	\$5,432,412
North Carolina	\$6,278,870	\$0	\$6,278,870
North Dakota	\$1,843,107	\$0	\$1,843,107
Northern Mariana Islands	\$544,494	\$0	\$544,494
Ohio	\$7,693,403	\$0	\$7,693,403
Oklahoma	\$3,431,303	\$0	\$3,431,303
Oregon	\$3,496,887	\$0	\$3,496,887
Palau	\$511,104	\$0	\$511,104

Awardee	Phase II Focus Area 1	Phase II Focus Area 2	FY 2009 PHER Phase II Funding Total
Pennsylvania	\$8,212,819	\$0	\$8,212,819
Puerto Rico	\$3,619,384	\$0	\$3,619,384
Rhode Island	\$2,076,070	\$0	\$2,076,070
South Carolina	\$3,831,697	\$0	\$3,831,697
South Dakota	\$1,921,915	\$0	\$1,921,915
Tennessee	\$4,758,470	\$0	\$4,758,470
Texas	\$14,184,535	\$0	\$14,184,535
Utah	\$2,875,985	\$0	\$2,875,985
Vermont	\$1,836,654	\$0	\$1,836,654
Virgin Islands (US)	\$558,602	\$0	\$558,602
Virginia	\$5,624,014	\$0	\$5,624,014
Washington	\$4,951,101	\$0	\$4,951,101
West Virginia	\$2,481,226	\$0	\$2,481,226
Wisconsin	\$4,498,228	\$0	\$4,498,228
Wyoming	\$1,777,890	\$0	\$1,777,890
TOTAL FY 2009 PHER Phase II Funding Total	\$248,000,000	\$0	\$248,000,000

Appendix 2
Public Health Emergency Response (PHER) Grant
Phase I and Phase II Application Dates*

Activity	Date	Mechanism
PHER Phase I Funding Application: Project Narrative, General Budget, Form SF-424A	July 24, 2009 Complete	www.grants.gov
PHER Phase I Notices of Awards – 50% of Funds Restricted*	July 31, 2009 Complete	Procurement and Grants Office (Funds Available via Payment Management System)
PERFORMS Templates Available for Gap Analysis and Work Plan	August 11, 2009	State and Local Readiness Mailbox
PHER Phase II Funding Application: Letter, General Budget, Form 424A	August 13, 2009	www.grants.gov
PHER Phase II Notices of Awards – 20% of Funds Restricted*	August 21, 2009	Procurement and Grants Office (Funds Available via Payment Management System)
PERFORMS Modules Open for Gap Analysis, Work Plan, Detailed Budget	August 21, 2009	PERFORMS
Completed Gap Analysis, Work Plan, Detailed Budget (Budget should reflect a combined PHER Phase I and Phase II budget for a 12-month period. Budget may include requests for direct assistance (DA) personnel.)	<i>On or Before</i> August 31, 2009	PERFORMS
*Restrictions Lifted on Remaining Phase I and Phase II Funds Following Approval of Gap Analysis, Work Plan, and Detailed Budget	Within 6-10 Days of Receipt of Materials	Procurement and Grants Office/ Division of State and Local Readiness (Funds Available via Payment Management System)
Letter Stating Comprehensive, Up-To-Date Mass Vaccination Plans Are in Place	September 15, 2009	PERFORMS

* Dates subject to change

Appendix 3
Division of State and Local Readiness Project Officers

HHS Region	Awardee	Project Officer	Telephone	Email
4	Alabama	Mark Green	404-639-7268	mlg5@cdc.gov
10	Alaska	Andrea Davis,	404-639-7177	goa9@cdc.gov
9	Arizona	Janice McMichael	404-639-7943	jrm6@cdc.gov
6	Arkansas	Andrea Davis	404-639-7177	goa9@cdc.gov
9	California	Clint Matthews	404-639-7638	div8@cdc.gov
5	Chicago	Terrance Jones	404-639-7047	tcj9@cdc.gov
8	Colorado	Terence Sutphin	404-639-7441	tus9@cdc.gov
1	Connecticut	Pete Hoffman	404-639-7305	zvp3@cdc.gov
3	Delaware	Trevia Brooks	404-639-7613	tnb9@cdc.gov
3	District of Columbia	Trevia Brooks	404-639-7613	tnb9@cdc.gov
4	Florida	Mark Green	404-639-7268	mlg5@cdc.gov
4	Georgia	Mark Green	404-639-7268	mlg5@cdc.gov
10	Idaho	Andrea Davis,	404-639-7177	goa9@cdc.gov
5	Illinois	Terrance Jones	404-639-7047	tcj9@cdc.gov
5	Indiana	Terrance Jones	404-639-7047	tcj9@cdc.gov
7	Iowa	Terence Sutphin	404-639-7441	tus9@cdc.gov
7	Kansas	Terence Sutphin	404-639-7441	tus9@cdc.gov
4	Kentucky	Mark Green	404-639-7268	mlg5@cdc.gov
9	Los Angeles	Clint Matthews	404-639-7638	div8@cdc.gov
6	Louisiana	Andrea Davis	404-639-7177	goa9@cdc.gov
1	Maine	Pete Hoffman	404-639-7305	zvp3@cdc.gov
3	Maryland	Trevia Brooks	404-639-7613	tnb9@cdc.gov
1	Massachusetts	Pete Hoffman	404-639-7305	zvp3@cdc.gov
5	Michigan	Terrance Jones	404-639-7047	tcj9@cdc.gov
5	Minnesota	Terrance Jones	404-639-7047	tcj9@cdc.gov
4	Mississippi	Mark Green	404-639-7268	mlg5@cdc.gov
7	Missouri	Terence Sutphin	404-639-7441	tus9@cdc.gov
8	Montana	Greg Smith	404-639-7703	gqs0@cdc.gov
7	Nebraska	Terence Sutphin	404-639-7441	tus9@cdc.gov
9	Nevada	Clint Matthews	404-639-7638	div8@cdc.gov
1	New Hampshire	Pete Hoffman	404-639-7305	zvp3@cdc.gov
2	New Jersey	Keesler King	404-639-7423	knk8@cdc.gov
6	New Mexico	Andrea Davis	404-639-7177	goa9@cdc.gov
2	New York City	Keesler King	404-639-7423	knk8@cdc.gov
2	New York State	Keesler King	404-639-7423	knk8@cdc.gov
4	North Carolina	Mark Green	404-639-7268	mlg5@cdc.gov
8	North Dakota	Greg Smith	404-639-7703	gqs0@cdc.gov
5	Ohio	Terrance Jones	404-639-7047	tcj9@cdc.gov
6	Oklahoma	Andrea Davis	404-639-7177	goa9@cdc.gov
10	Oregon	Andrea Davis,	404-639-7177	goa9@cdc.gov
3	Pennsylvania	Trevia Brooks	404-639-7613	tnb9@cdc.gov
2	Puerto Rico	Keesler King	404-639-7423	knk8@cdc.gov

HHS Region	Awardee	Project Officer	Telephone	Email
1	Rhode Island	Pete Hoffman	404-639-7305	zvp3@cdc.gov
4	South Carolina	Mark Green	404-639-7268	mlg5@cdc.gov
8	South Dakota	Greg Smith	404-639-7703	gqs0@cdc.gov
4	Tennessee	Mark Green	404-639-7268	mlg5@cdc.gov
6	Texas	Andrea Davis	404-639-7177	ecq5@cdc.gov
8	Utah	Greg Smith	404-639-7703	gqs0@cdc.gov
1	Vermont	Pete Hoffman	404-639-7305	zvp3@cdc.gov
2	Virgin Islands	Keesler King	404-639-7423	knk8@cdc.gov
3	Virginia	Trevia Brooks	404-639-7613	tnb9@cdc.gov
10	Washington	Andrea Davis,	404-639-7177	goa9@cdc.gov
3	West Virginia	Trevia Brooks	404-639-7613	tnb9@cdc.gov
5	Wisconsin	Terrance Jones	404-639-7047	tcj9@cdc.gov
8	Wyoming	Greg Smith	404-639-7703	gqs0@cdc.gov
	Pacific Islands			
9	Palau	Janice McMichael	404-639-7943	jrm6@cdc.gov
9	CNMI	Janice McMichael	404-639-7943	jrm6@cdc.gov
9	FSM	Janice McMichael	404-639-7943	jrm6@cdc.gov
9	Guam	Janice McMichael	404-639-7943	jrm6@cdc.gov
9	Hawaii	Janice McMichael	404-639-7943	jrm6@cdc.gov
9	Marshall Islands	Janice McMichael	404-639-7943	jrm6@cdc.gov
9	American Samoa	Janice McMichael	404-639-7943	jrm6@cdc.gov

Appendix 4
Procurement and Grants Office Grants Management Specialists

Specialist

Angela Webb

Phone: (770) 488-2784

Email: aqw6@cdc.gov

Grant #	Awardee
000325	Illinois
000376	Ohio
000379	Chicago
000353	Michigan
000339	Indiana
000362	Texas
000368	Louisiana
000350	Los Angeles
000330	Hawaii
000332	California

Specialist

Glynnis Taylor

Phone: (770) 488-2752

Email: gld1@cdc.gov

Grant #	Awardee
000328	Alaska
000345	Oregon
000369	Washington
000366	Idaho
000333	South Carolina
000338	Alabama
000355	Kentucky
000134	Mississippi
000342	Iowa
000360	Missouri
000381	Nebraska
000344	Kansas
000352	Colorado
000377	Montana
000346	Utah
000365	Wyoming
000326	South Dakota
000358	North Dakota
000337	Nevada
000334	Arizona

000386	Guam
000354	Commonwealth of the Northern Mariana Islands
000374	Marshall Islands
000331	Palau
000323	Federated States of Micronesia
000383	American Samoa

Specialist

Kaleema McLean
Phone: (770) 488-2742
Email: fya3@cdc.gov

Grant #	Awardee
000382	Rhode Island
000340	Delaware
000349	Tennessee
000348	Minnesota

Specialist

Pamela Baker
Phone: (770) 488-2689
Email: fxz7@cdc.gov

Grant #	Awardee
000343	Vermont
000341	Maine
000375	New Hampshire
000372	New Jersey
000356	West Virginia
000359	Virginia
000327	Maryland
000363	Wisconsin
000335	Arkansas
000329	Oklahoma
000364	New Mexico

Specialist

Sharon Robertson
Phone: (770) 488-2748
Email: sqr2@cdc.gov

Grant #	Awardee
000367	Connecticut
000378	Massachusetts
000347	New York State
000385	New York City
000371	Virgin Islands
000370	Puerto Rico

000373	District of Columbia
000361	Pennsylvania
000357	North Carolina
000351	Florida
000384	Georgia